Prevention of Olanzapine-induced Toxicities of Weight Gain and Inflammatory Reactions by Coadministration with Green Tea or its Major Component Phenolic Epigallocatechin 3-Gallate in Mouse

  • Kim, Chul-Eung (Department of Psychiatry, Medicinal Toxicology Research Center, Center for Advanced Medical Education, Inha University College of Medicine by BK-21 project) ;
  • Mo, Ji-Won (Department of Pharmacology, Medicinal Toxicology Research Center, Center for Advanced Medical Education, Inha University College of Medicine by BK-21 project) ;
  • Kim, Jin (Department of Pharmacology, Medicinal Toxicology Research Center, Center for Advanced Medical Education, Inha University College of Medicine by BK-21 project) ;
  • Kang, Ju-Hee (Department of Pharmacology, Medicinal Toxicology Research Center, Center for Advanced Medical Education, Inha University College of Medicine by BK-21 project) ;
  • Park, Chang-Shin (Department of Pharmacology, Medicinal Toxicology Research Center, Center for Advanced Medical Education, Inha University College of Medicine by BK-21 project)
  • Published : 2007.06.30

Abstract

Chronic treatment with olanzapine (OLZ), an atypical antipsychotic drug, is associated with the adverse effects of weight gain, hyperglycemia and/or hypertriglyceridemia. Green tea or epigallocatechin gallate (EGCG), one of the most abundant green tea polyphenols, significantly reduces or prevents an increase in glucose levels, lipid markers and/or body weight. We hypothesized that combined treatment with OLZ and green tea extract (GTE) or EGCG may prevent body weight gain and increase of the lipid markers. ICR male mice weighing an average of 30.51 g (n=32) at the beginning of the experiment were used. OLZ, OLZ+GTE and OLZ+EGCG were administered for 27 d in the drinking water, and then the levels of fasting glucose, nitric oxide (NO), and a typical lipid marker triglyceride (TG) were determined in plasma. The body weight and food intake were also compared. The chronic treatment of OLZ increased the average body weight compared with that of controls. In the presence of GTE or EGCG, the OLZ-induced increase in body weight was significantly prevented. Furthermore, in the OLZ group, the plasma levels of glucose, NO and TG were significantly increased, whereas GTE or EGCG prevented these increases. These results implicate that OLZ may induce systematic inflammatory reaction, and suggest that GTE or EGCG can protect against OLZinduced weight gain, hyperglycemia and hypertriglyceridemia.

Keywords

References

  1. Bell, S. J. & Goodrick, G. K. A functional food product for the management of weight. Crit. Rev. Food. Sci. Nutr. 42:163-178 (2002) https://doi.org/10.1080/10408690290825501
  2. Blum, W. F. Leptin: the voice of the adipose tissue. Horm. Res. 48:2-8 (1997)
  3. Chantre, P. & Lairon, D. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Phytomedicine 9:1-6 (2002)
  4. Choi, J. W. et al. Increases in nitric oxide concentrations correlate strongly with body fat in obese humans. Clin. Chem. 47:1106-1109 (2001)
  5. Dulloo, A.G. et al. Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity. Int. J. Obes. Relat. Metab. Disord. 24:252-258 (2000) https://doi.org/10.1038/sj.ijo.0801101
  6. Dulloo, A. G. et al. Efficacy of GT extract rich in catethin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am. J. Clin. Nutr. 70:1040-1045 (1999) https://doi.org/10.1093/ajcn/70.6.1040
  7. Dulloo, A. G. & Miller, D. S. The thermogenic properties of ephedrine/methylxanthine mixtures: human studies. Int. J. Obes. 10:467-481 (1986)
  8. Eder, U. et al. Association of olanzapine-induced weight gain with an increase in body fat. Am. J. Psychiatry 158:1719-1722 (2001) https://doi.org/10.1176/appi.ajp.158.10.1719
  9. Gaudiot, N. et al. Modulation of white adipose tissue lipolysis by nitric oxide. J. Biol. Chem. 273:13475- 13481 (1998) https://doi.org/10.1074/jbc.273.22.13475
  10. Ghaeli, P. & Dufresne, R. L. Elevated serum triglycerides on clozapine resolve with risperidone. Pharmacotherapy 1:382-385 (1995)
  11. Green, A. I. et al. Weight gain from novel antipsychotic drugs: Need for action. Gen. Hosp. Psychiatry 22:224-235 (2000) https://doi.org/10.1016/S0163-8343(00)00081-5
  12. Green, L. C. et al. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 126: 131-138 (1982) https://doi.org/10.1016/0003-2697(82)90118-X
  13. Masand, P. S. & Gupta, S. Long-term adverse effects of novel antipsychotics. J. Psychiatr. Pract. 6:299- 309 (2000) https://doi.org/10.1097/00131746-200011000-00001
  14. Kao, Y. H., Hiipakka, R. A. & Liao, S. Modulation of obesity by a green tea catechin. Am. J. Clin. Nutr. 72:1232-1233 (2000a) https://doi.org/10.1093/ajcn/72.5.1232
  15. Kao, Y. H., Hiipakka, R. A. & Liao, S. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology 141:980-987 (2000b) https://doi.org/10.1210/en.141.3.980
  16. Melkersson, K. I. & Hulting, A. L. Insulin and leptin levels in patients with schizophrenia or related psychoses- a comparison between different antipsychotic agents. Psychopharmacology 154:205-212 (2001) https://doi.org/10.1007/s002130000639
  17. Meyer, J. M. Novel antipsychotics and severe hyperlipidemia. J. Clin. Psychopharmacol. 21:369-374 (2001) https://doi.org/10.1097/00004714-200108000-00003
  18. Mitscher, L. A. et al. Chemoprevention: a review of the potential therapeutic antioxidant properties of green tea and certain of its constituents. Med. Res. Rev. 17:327-365 (1997) https://doi.org/10.1002/(SICI)1098-1128(199707)17:4<327::AID-MED2>3.0.CO;2-Y
  19. Newcomer, J. W. et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry 59:337-345 (2002) https://doi.org/10.1001/archpsyc.59.4.337
  20. Osser, D. O., Najarian, D. M. & Dufresne, R. L. Olanzapine increases weight and serum triglycerides. J. Clin. Psychiatry 60:767-770 (1999) https://doi.org/10.4088/JCP.v60n1109
  21. Ratzoni, G. et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J. Am. Acad. Child Adolesc Psychiatry 41:337-343 (2002) https://doi.org/10.1097/00004583-200203000-00014
  22. Remschmidt, H. et al. Atypical neuroleptics in child and adolescent psychiatry. Eur. Child Adolescent Psychiatry 9:119 (2000)
  23. Uchida, Y. et al. Nitric oxide mediates down regulation of lipoprotein lipase activity induced by tumor necrosis factor-alpha in brown adipocytes. Eur. J. Pharmacol. 335:235-243 (1997) https://doi.org/10.1016/S0014-2999(97)01181-3
  24. Verdon, C. P., Burton, B. A. & Prior, R. L. Sample pretreatment with nitrate reductase and glucose-6- phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+ when the Griess reaction is used to assay for nitrite. Anal. Biochem. 224:502-508 (1995) https://doi.org/10.1006/abio.1995.1079
  25. Wirshing, D. A. et al. Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry 60:358-363 (1999) https://doi.org/10.4088/JCP.v60n0602
  26. Jang, E. H. et al. Effects of green tea extract administration on the pharmacokinetics of clozapine in rats. J. Pharm. Pharmacol. 57:311-316 (2005) https://doi.org/10.1211/0022357055687
  27. Ryu, J. C., Kim, M. K., Choi, M. H. & Chun, T. H. Promising next generation technology in toxicologytoxicogenomics. Mol. Cell. Toxicol. 1:1-6 (2005)
  28. Jung, W. W. et al. Development of proteomics and applications of proteomics in toxicology. Mol. Cell. Toxicol. 1:7-12 (2005)